Research on how long people stay on a GLP-1 uses several measures of persistence. An Australian service examined fulfilled semaglutide orders before and after it launched an AI support agent [1].
Two comparisons from the same records
The study used records for 16,556 adults. Six-month adherence was 53.2% after launch and 47.3% before launch in the unadjusted comparison [1].
The postlaunch period was associated with higher odds of attrition after adjustment for measured factors. The odds ratio was 1.178 (95% CI 1.052 to 1.318). A matched analysis also found higher odds of attrition after launch.
What the study can tell us about support
A separate study of digital engagement and persistence tracked patients in a French early-access program. Both studies examined patterns in engagement without assigning patients to use the digital tools.
The Australian study counted fulfilled orders as its adherence measure. Its comparison cannot isolate the effect of the support agent from other changes over time. Some authors were affiliated with Eucalyptus Health and Amigo AI.